<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Symptom Advice .com &#187; january 4</title>
	<atom:link href="http://symptomadvice.com/tag/january-4/feed/" rel="self" type="application/rss+xml" />
	<link>http://symptomadvice.com</link>
	<description></description>
	<lastBuildDate>Tue, 29 May 2012 22:17:13 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.0.1</generator>
		<item>
		<title>Almirall and Forest Announce Positive Results from the ATTAIN Phase III Study of Aclidinium Bromide and the Phase IIb Studies With the Fixed Dose Combination with Formoterol in Moderate to Severe COPD</title>
		<link>http://symptomadvice.com/almirall-and-forest-announce-positive-results-from-the-attain-phase-iii-study-of-aclidinium-bromide-and-the-phase-iib-studies-with-the-fixed-dose-combination-with-formoterol-in-moderate-to-severe-copd/</link>
		<comments>http://symptomadvice.com/almirall-and-forest-announce-positive-results-from-the-attain-phase-iii-study-of-aclidinium-bromide-and-the-phase-iib-studies-with-the-fixed-dose-combination-with-formoterol-in-moderate-to-severe-copd/#comments</comments>
		<pubDate>Wed, 05 Jan 2011 15:17:10 +0000</pubDate>
		<dc:creator>Symptom Advice</dc:creator>
				<category><![CDATA[nervous symptoms]]></category>
		<category><![CDATA[january 4]]></category>
		<category><![CDATA[regulatory filings]]></category>

		<guid isPermaLink="false">http://symptomadvice.com/almirall-and-forest-announce-positive-results-from-the-attain-phase-iii-study-of-aclidinium-bromide-and-the-phase-iib-studies-with-the-fixed-dose-combination-with-formoterol-in-moderate-to-severe-copd/</guid>
		<description><![CDATA[BARCELONA &#097;&#110;&#100; NEW YORK, January 4, 2011 /PRNewswire/ &#8211; &#8211; ATTAIN results confirm clinically significant bronchodilation &#097;&#110;&#100; improvement ofsymptoms in COPD patients treated with aclidinium bromide twice daily &#8211; Regulatory filings in Europe &#097;&#110;&#100; USA for aclidinium bromide monotherapy &#097;&#114;&#101; &#112;&#108;&#097;&#110;&#110;&#101;&#100; for mid 2011 &#8211; Positive results &#111;&#102; &#116;&#119;&#111; Phase IIb studies with &#116;&#104;&#101; fixed [...]]]></description>
			<content:encoded><![CDATA[<p></p><p><img src="http://symptomadvice.com/wp-content/uploads/2011/01/1294240630-98.jpg%3Fw%3D600%26h%3D766" style="clear:both;clear:both;margin:0 15px 15px 0;width:500px" />
<p>BARCELONA &#097;&#110;&#100; NEW YORK, January 4, 2011 /PRNewswire/ &#8211;</p>
<p> &#8211; ATTAIN results confirm clinically significant bronchodilation &#097;&#110;&#100; improvement ofsymptoms in COPD patients treated with aclidinium bromide twice daily &#8211; Regulatory filings in Europe &#097;&#110;&#100; USA for aclidinium bromide monotherapy &#097;&#114;&#101; &#112;&#108;&#097;&#110;&#110;&#101;&#100; for mid 2011 &#8211; Positive results &#111;&#102; &#116;&#119;&#111; Phase IIb studies with &#116;&#104;&#101; fixed dose combination &#111;&#102; aclidinium bromide &#097;&#110;&#100; formoterol will enable Phase III &#116;&#111; start in &#115;&#101;&#099;&#111;&#110;&#100; half 2011
<p> Almirall, S.A. (ALM.MC) &#097;&#110;&#100; Forest Laboratories, Inc. today announced positive top-line results &#111;&#102; ATTAIN, a six month double-blind placebo-controlled pivotal Phase III study comparing &#116;&#104;&#101; efficacy &#097;&#110;&#100; safety &#111;&#102; inhaled aclidinium bromide 200 micrograms &#097;&#110;&#100; 400 micrograms twice daily (BID) versus placebo, in 828 patients with moderate &#116;&#111; severe COPD. </p>
<p> Aclidinium 200 micrograms &#097;&#110;&#100; 400 micrograms produced statistically significant increases &#102;&#114;&#111;&#109; baseline in morning pre-dose (trough) FEV1 versus placebo &#097;&#116; week 24 (99mL &#097;&#110;&#100; 128mL, respectively; p</p>
]]></content:encoded>
			<wfw:commentRss>http://symptomadvice.com/almirall-and-forest-announce-positive-results-from-the-attain-phase-iii-study-of-aclidinium-bromide-and-the-phase-iib-studies-with-the-fixed-dose-combination-with-formoterol-in-moderate-to-severe-copd/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
